Published online before print October 17, 2002, doi: 10.1161/01.RES.0000042062.69653.E4
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
UltraRapid Communication |
Deficiency in ClC-3 Chloride Channels Prevents Rat Aortic Smooth Muscle Cell Proliferation
From the Department of Pharmacology, Zhongshan Medical College, Sun Yat-Sen University, Guangzhou, People’s Republic of China.
Correspondence to Dr Yong-Yuan Guan, Prof, Dept of Pharmacology, Sun Yat-Sen University, Zhongshan Medical College, 74 Zhongshan 2 Rd, Guangzhou, Guangdong 510089, P.R. China. E-mail yyguan{at}gzsums.edu.cn
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Recent growing evidence suggests that chloride (Cl-) channels are critical to the cell cycle. In cultured rat aortic vascular smooth muscle cells (VSMCs), we have previously found that Cl- channel blockers inhibit endothelin-1 (ET-1)–induced cell proliferation. The present study was designed to further identify the specific Cl- channels responsible for VSMC proliferation. Due to the lack of a specific blocker or opener of any known Cl- channels, we used the antisense strategy to investigate the potential role of ClC-3, a member of the voltage-gated Cl- channel gene family, in cell proliferation of cultured rat aortic VSMCs. With [3H]-thymidine incorporation and immunoblots, we found that ET-1–induced cell proliferation was parallel to a significant increase in the endogenous expression of ClC-3 protein. Transient transfection of rat aortic VSMCs with antisense oligonucleotide specific to ClC-3 caused an inhibition in ET-1–induced expression of ClC-3 protein and cell proliferation of VSMCs in the same concentration- and time-dependent pattern, whereas sense and missense oligonucleotides resulted in no effects on ClC-3 protein expression and cell proliferation. These results strongly suggest that ClC-3 may be the Cl- channel involved in VSMC proliferation and thus provide compelling molecular evidence linking a specific Cl- channel to cell proliferation. The full text of this article is available at http://www.circresaha.org.
Key Words: vascular smooth muscle • chloride channel • proliferation • gene expression
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Vascular smooth muscle cell (VSMC) proliferation is a key event in the pathogenesis of arteriosclerosis and many other vascular diseases.1–3 Endothelin-1 (ET-1), a natural potent vasoconstrictor and comitogen/proliferation factor for VSMCs, has been shown to induce VSMC proliferation in cultured rat and human aortic smooth muscle cells.4,5 The mitogenic effect of ET-1 has also been related with the vascular remodeling involved in the pathogenesis of vascular diseases such as hypertension and atherosclerosis.6–9 Many ion channels may be involved in ET-1–induced cell proliferation. For example, electrophysiological studies in systemic vascular smooth muscle cells demonstrate that ET-1 can activate L-type Ca2+ channels and receptor-operated Ca2+ channels and promote cell proliferation.10,11 Recent growing evidence indicates that Cl- channels may also play critical role in regulation of the cell cycle.12–17 In our previous studies,17 we have examined the effects of different kinds of Cl- channel blockers on the proliferation of VSMCs induced by ET-1. We found only 4,4'-diisothiocyanostilbene-2, 2'-disulfonic acid (DIDS) significantly inhibited ET-1–induced proliferation of VSMCs in a concentration-dependent manner (0.1 µmol/L to 1 mmol/L), whereas other Cl- channel blockers such as IAA-94, NPPB, DPC, and furosemide had no significant inhibitory effect on VSMC proliferation under the same concentrations. These data indicate that DIDS-sensitive Cl- channels may be involved in ET-1–induced VSMC proliferation.
At least two types of DIDS-sensitive Cl- channels, including a calcium-activated Cl- channel (ICl,Ca) and a volume-regulated Cl- channel (ICl.Vol), have been previously described in VSMCs.18–20 It is still not clear which type of Cl- channel is associated with VSMC proliferation, although recent studies have shown the involvement of ICl,Vol in cell proliferation in many other cell types, such as rat C6 glioma,15 liver,16 T lymphocytes,21 and endothelial cells.22
At a molecular level, among the identified Cl- channels in VSMCs, ClC-3, a member of the ClC superfamily of chloride channels, has been found to be the dominant Cl- channel in human vascular smooth muscle.23,24 The ClC-3 current exhibits the properties including outward rectification, activation by extracellular hypotonicity, inhibition by DIDS, and tamoxifen, similar to that of ICl,Vol in cardiac myocytes and VSMCs.13,22 Inhibition of endogenous ClC-3 expression using antisense oligonucleotide against ClC-325 or anti-ClC-3 antibody26 causes a significant decrease in ICl,Vol in smooth muscle cells. We hypothesized, therefore, that Cl- channels encoded by ClC-3 might contribute to ET-1–induced VSMC proliferation. To test this hypothesis, we used multiple proliferation assays, immunoblot, and antisense strategy to examine (1) whether ClC-3 protein is endogenously expressed in cultured rat aortic VSMCs; (2) whether the endogenous expression of ClC-3 is enhanced by ET-1; and (3) what the relationship between the expression of ClC-3 and VSMC proliferation induced by ET-1 would be. Our results demonstrate that ET-1 stimulates VSMC proliferation and ClC-3 protein expression, and deficiency in endogenous ClC-3 caused by antisense oligonucleotide prevented the ET-1–induced ClC-3 VSMC proliferation.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell Culture
Wistar rats were supplied by the Experimental Animal Center of Sun Yat-Sen University in Guangzhou, China. All procedures complied with the standards for the care and use of animal subjects as stated in the Guide for the Care and Use of Laboratory Animals (issued by the Ministry of Science and Technology of China, Beijing). VSMCs were isolated and cultured from rat thoracic aorta as previously described.3,17 Passage 8 to 14 VSMCs at 70% to 90% confluence in 35-mm dishes or 96-well plates were growth-arrested by incubation in 0.2% calf serum/DMEM for 72 hours. Cells were identified as smooth muscle cells by morphology and immunostaining with monoclonal antibody specific for smooth muscle
-actin.
Transfection of the VSMCs With Antisense, Sense, or Missense Oligonucleotides
The antisense and sense oligonucleotides corresponding specifically to the initiation codon region of the human ClC-3 mRNA were synthesized (Sangon, Shanghai, China) as reported previously.25 The antisense sequence was 5'-TCCATTTGTCATTGT-3'. The sense oligonucleotide had the sequence 5'-ACAATGACAAATGGA-3'. We designed missense oligonucleotide 5'-TCTATTCCTGTATTG-3', which consisted of the same bases as used in the antisense probe but in a random order, and did not recognize any known sequence available in GenBank. The first three bases at either end in all oligonucleotides were phosphorothioated. To examine the uptake of oligonucleotide by VSMCs, the oligonucleotides were labeled with fluorescence. For transient transfection, the cells in the quiescent state were transfected with oligonucleotides by incubation for 24 hours with lipofectamine 2000 (5 µL/mL, Life Technologies, Inc.). Cells were switched to the 0.2% FCS-containing medium with or without various concentration of ET-1.
[3H]-Thymidine Incorporation
To examine the DNA synthesis, rat aortic VSMCs, either rendered quiescent or transfected with antisense or sense oligonucleotides, were incubated with ET-1 in DMEM/0.2% FBS medium for 18 hours, then 1 µCi/mL [3H]-thymidine was added to the medium for a further 6-hour incubation. TCA-insoluble radioactivity was counted with Beckman liquid scintillation counter. To exclude possible toxicity, lipofectamine 2000, antisense, sense, and missense oligonucleotides were incubated with VSMCs, respectively, and radioactivity was counted. No toxicity was detected at the concentrations used in present study.
Western Blot Analysis
To examine ClC-3 protein expression, rat aortic VSMCs were washed with PBS and lysis buffer: Tris-Cl 50 mmol/L, NaCl 150 mmol/L, NaN3 0.02%, Nonidet P-40 1%, SDS 0.1%, sodium deoxycholate 0.5%, 5 µg/mL leupeptin, and 1 µg/mL aprotinin. The protein content of cell lysates was quantified with Coomassie Brilliant Blue, and separated by SDS-PAGE and transferred to nitrocellulose membranes (Schleicher & Schuell). The membranes were blocked at room temperature (24°C to 26°C) for 1 hour in PBST (in mmol/L: NaCl 130, KCl 2.5, Na2HPO4 10, KH2PO4 1.5, 0.1% Tween 20, and 5% BSA, pH 7.4), incubated initially with primary antibodies (anti-ClC-3, Alomone Labs, 1 hour at room temperature or overnight at 4°C), and then with the appropriate secondary peroxidase-conjugated antibodies (HRP-linked anti-rabbit secondary antibody and HRP-linked anti-biotin antibody, 1 hour at room temperature). Final detection was carried out with LumiGLO chemiluminescent reagent (New England Biolabs) as described by the manufacturer. The density of target bands were accurately determined by the computer-aided 1-D gel analysis system.
Statistical Analysis
All data are expressed as mean±SEM. Statistical analyses were performed using Student’s t test or ANOVA. Values of P<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
ET-1 Induced Endogenous ClC-3 Expression
Expression of ClC-3 protein in VSMCs was detected by immunoblotting with the use of a polyclonal antibody directed against ClC-3. The anti–ClC-3 antibody recognized a major band at 80 to 90 kDa (Figure 1). Then, we examined whether ET-1 could functionally enhance endogenous ClC-3 expression. As shown in Figure 1, ET-1 (10-8 mol/L) stimulated the expression of ClC-3 protein in a time-dependent manner. Compared with relative controls, at 24, 48, and 72 hours, the ClC-3 protein expressions were elevated 1.05±0.11-fold (P>0.05, n=4), 2.89±0.43-fold (P<0.01, n=4), and 2.72±0.50-fold (P<0.01, n=4), respectively. The ClC-3 protein expression reached the maximal expression level at 48 hours. These results suggest that ET-1–induced VSMC proliferation is closely associated with a corresponding increase in endogenous ClC-3 protein expression. To be consistent with the studies in proliferation assay,17 we chose ET-1 stimulation for 48 hours in subsequent experiments.
|
Antisense Oligonucleotide Inhibits ET-1–Induced ClC-3 Protein Expression
Because there exists no specific ClC-3 chloride channel blockers, we used antisense oligonucleotide specifically against ClC-3 to inhibit endogenous ClC-3 protein expression. To examine the uptake of oligonucleotide by VSMCs, the oligonucleotides were labeled with fluorescence. As shown in Figure 2, under resting conditions the fluorescence in the cells was negligible, but the fluorescence in cells treated with antisense, sense, or missense were greatly increased, which confirmed the uptake of oligonucleotides by these cells. Figure 3 illustrates ET-1–induced ClC-3 protein expression was decreased by 36±8%, 59±7%, and 68±8% (n=7) in 5 µL/mL lipofectamine plus 25, 50, and 100 µg/mL ClC-3 antisense oligonucleotides, respectively. To exclude the nonspecificity of antisense oligonucleotide, the sense and missense oligonucleotide were synthesized and their effects on ClC-3 protein expression were examined. The sense or missense probe had no significant effects on ET-1–induced ClC-3 protein expression (Figure 4; P>0.05, n=5). Figure 3 also illustrates that there was no significant effect of transfection agent lipofectamine (5 µL/mL) alone on ET-1–induced ClC-3 protein expression (P>0.05, n=4).
|
|
P>0.05 vs ET-1; #P<0.01 vs control; **P<0.01 vs ET-1.
|
Inhibition of ET-1–Induced Cell Proliferation by Antisense Oligonucleotides Against ClC-3
The misogynic effect of ET-1 on VSMCs was examined by cell count and [3H]-thymidine incorporation into DNA synthesis as described in our previous studies. ET-1 stimulated the proliferation of VSMCs in a concentration-dependent manner (10-10 mol/L to 10-6 mol/L).17 As shown in Figure 4, 10-8 mol/L ET-1 increased [3H]-thymidine incorporation to 3.6±0.4-fold higher than that in ET-1–free medium. To test the efficacy of antisense oligonucleotide as an inhibitor of proliferation, we transfected the VSMCs with the sense, antisense, or missense oligonucleotides, respectively. The incorporation of [3H]-thymidine induced by ET-1 was significantly inhibited by ClC-3 antisense oligonucleotide, also concentration-dependently (Figure 4), 200 µg/mL antisense oligonucleotide produced maximal effects, with the maximal inhibitory rate of 70±7% (n=9). To exclude the nonspecificity of the oligonucleotides and/or transfection reagent had antiproliferative effects on VSMCs, cells were incubated with lipofectamine alone for 24 hours or with sense and missense oligonucleotide respectively for 48 hours. No significant inhibition of ET-1–induced [3H]-thymidine incorporation were observed (Figure 4; P>0.05, n=9).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Our results provide compelling evidence that ClC-3 Cl- channels are critically linked to ET-1–induced VSMC proliferation. We first used Western blot and proliferation assay to demonstrate that ClC-3 is endogenously expressed in rat aortic VSMCs. Then, we found that ET-1–induced cell proliferation was accompanied by an increase in ClC-3 expression in the same concentration- and time-dependent pattern. Finally, antisense, but neither sense nor missense, oligonucleotides against ClC-3 not only inhibited the ET-1–induced expression of ClC-3 protein but also decreased [3H]-thymidine incorporation and prevented VSMC proliferation.
It is well known that most cells swell during the early phase of cell proliferation probably caused by water influx that accompanies changes in cell metabolism (such as obligatory uptake of amino acids) in the cell cycle. An increase in cell volume usually initiates the so-called regulatory volume decrease (RVD) process through activation of ion (K+ and Cl-) channels and transporters, which moves K+ and Cl- out of the cell to balance the water influx and returns the cell volume to its normal size. Theoretically, therefore, activation of ICl.vol may play an essential role in cell proliferation. In fact, recent studies have clearly shown that Cl- channel blockers inhibit not only ICl.vol but also cell proliferation and [3H]-thymidine incorporation in many cell types, including glioma cells,15 hepatocytes,16 fibroblasts,18 T lymphocytes,21 endothelial cells,22 breast cancer,27 and microglial cells.28 Similarly, our previous study indicates that a widely used Cl- channel blocker, DIDS, also inhibits cell proliferation and [3H]-thymidine incorporation in rat aortic VSMCs.17 Due to the lack of specificity of the Cl- channel blockers used in these studies and the concomitant expression of several types of Cl- channel in the same cell, however, it is almost impossible to draw a definitive conclusion that the effects of these channel blockers are due to the blockade of ICl.vol alone. For example, DIDS has been found to block not only ICl.vol but also ICl.Ca and several cation channels (such as L-type Ca2+ channels) as well.29,30
In cardiac and vascular smooth myocytes and many other cell types, ClC-3 Cl- channel has been confirmed to encode ICl.vol,18,20,24–26,31–35 although conflicting results have been reported on the function and cellular localization of ClC-3 channels.25 When expressed in mammalian cell lines, ClC-3 mediates a DIDS-sensitive outwardly rectifying Cl- current.18 In human blood vessels, ClC-3 is the most abundantly expressed Cl- channel that may underlie the native swelling-activated Cl- current found in these tissues.23 Antisense oligonucleotide against ClC-3 has been shown to significantly inhibit the swelling-activated Cl- current and the functional regulatory volume decrease in HeLa cells, Xenopus laevis oocytes,31 and nonpigmented ciliary epithelial cells.25 Using the previously reported ClC-3 antisense oligonucleotide25 to specifically inhibit the functional expression of ClC-3 in the cultured rat aortic VSMCs, we now find that deficiency in ClC-3 expression prevents cell proliferation and [3H]-thymidine incorporation. Because it has been consistently reported from many independent investigators, as mentioned earlier, that ICl.vol is closely associated with cell proliferation in many cell types, our present work provides further evidence to support the notion that ClC-3 may be the gene responsible for ICl.vol in these cell types. Although it is still not clear how the ClC-3 channels are involved in VSMC proliferation, our results strongly suggest that ClC-3 channels, or ICl.vol, are important regulators of the cell cycle and may play substantially crucial role in such pathogenic process as hypertension and arteriosclerosis when VSMC proliferation is important in the development of vascular modeling.
|
Acknowledgments |
|---|
This work was sponsored by Science Foundation of the Ministry of Science and Technology in China, by National Natural Science Foundation of China (No. 39970849), by Natural Science Foundation of Guangdong Province, China (No. 001391), and by Team-Work Program from Natural Science Foundation of Guangdong Province.
Received September 10, 2001; revision received October 7, 2002; accepted October 7, 2002.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Fischer-Dzoga K. Cellular proliferation, cellular death and atherosclerosis. Artery. 1979; 5: 222–236.[Medline] [Order article via Infotrieve]
2. Jackson CL, Schwartz SM. Pharmacology of smooth muscle cell replication. Hypertension. 1992; 20: 713–736.
3. Ross R. The pathogenesis of atherosclerosis–an update. N Engl J Med. 1986; 314: 488–500.[Medline] [Order article via Infotrieve]
4. Fujitani Y, Ninomiya H, Okada T, Urade Y, Masaki T. Suppression of endothelin-1–induced mitogenic responses of human aortic smooth muscle cells by interleukin-1ß. J Clin Invest. 1995; 95: 2474–2482.[CrossRef][Medline] [Order article via Infotrieve]
5. Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249–252.[CrossRef][Medline] [Order article via Infotrieve]
6. Chen YF, Oparil S. Endothelin and pulmonary hypertension. J Cardiovasc Pharmacol. 2000; 35: S49–S53.[Medline] [Order article via Infotrieve]
7. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 1999; 92: 1–20.[CrossRef]
8. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med. 1999; 221: 312–325.[CrossRef][Medline] [Order article via Infotrieve]
9. Okamoto Y, Satomura K, Nakamura H, Takeuchi K, Yoshioka M. Changes in the proliferative activities of cells in experimental atherosclerotic plaques during remodeling. J Atheroscler Thromb. 1998; 5: 7–12.[Medline] [Order article via Infotrieve]
10. Golovina VA, Platoshyn O, Bailey CL, Wang J, Limsuwan A, Sweeney M, Rubin LJ, Yuan JX. Upregulated TRP and enhanced capacitative Ca2+ entry in human pulmonary artery myocytes during proliferation. Am J Physiol Heart Circ Physiol. 2001; 280: H746–H755.
11. Zhang XF, Iwamuro Y, Enoki T, Okazawa M, Lee K, Komuro T, Minowa T, Okamoto Y, Hasegawa H, Furutani H, Miwa S, Masaki T. Pharmacological characterization of Ca2+ entry channels in endothelin-1–induced contraction of rat aorta using LOE 908 and SK&F 96365. Br J Pharmacol. 1999; 127: 1388–1398.[CrossRef][Medline] [Order article via Infotrieve]
12. Furukawa T, Ogura T, Zheng YJ, Tsuchiya H, Nakaya H, Katayama Y, Inagaki N. Phosphorylation and functional regulation of ClC-2 chloride channels expressed in Xenopus oocytes by M cyclin-dependent protein kinase. J Physiol. 2002; 540: 883–893.
13. Maertens C, Droogmans G, Chakraborty P, Nilius B. Inhibition of volume-regulated anion channels in cultured endothelial cells by the anti-oestrogens clomiphene and nafoxidine. Br J Pharmacol. 2001; 132: 135–142.[CrossRef][Medline] [Order article via Infotrieve]
14. Nilius B. Chloride channels go cell cycling. J Physiol. 2001; 532: 581.
15. Rouzaire-Dubois B, Milandri JB, Bostel S, Dubois JM. Control of cell proliferation by cell volume alterations in rat C6 glioma cells. Pflugers Arch. 2000; 440: 881–888.[CrossRef][Medline] [Order article via Infotrieve]
16. Wondergem R, Gong W, Monen SH, Dooley SN, Gonce JL, Conner TD, Houser M, Ecay TW, Ferslew KE. Blocking swelling-activated chloride current inhibits mouse liver cell proliferation. J Physiol. 2001; 532: 661–672.
17. Xiao GN, Guan YY, He H. Effects of Cl- channel blockers on endothelin-1–induced proliferation of rat vascular smooth muscle cells. Life Sci. 2002; 70: 2233–2241.[CrossRef][Medline] [Order article via Infotrieve]
18. Duan D, Winter C, Cowley S, Hume JR, Horowitz B. Molecular identification of a volume-regulated chloride channel. Nature. 1997; 390: 417–421.[CrossRef][Medline] [Order article via Infotrieve]
19. Hirakawa Y, Gericke M, Cohen RA, Bolotina VM. Ca2+-dependent Cl- channels in mouse and rabbit aortic smooth muscle cells: regulation by intracellular Ca2+ and NO. Am J Physiol. 1999; 277: H1732–H1744.[Medline] [Order article via Infotrieve]
20. Lamb FS, Barna TJ. The endothelium modulates the contribution of chloride currents to norepinephrine–induced vascular contraction. Am J Physiol. 1998; 275: H161–H168.[Medline] [Order article via Infotrieve]
21. Phipps DJ, Branch DR, Schlichter LC. Chloride-channel block inhibits T lymphocyte activation and signalling. Cell Signal. 1996; 8: 141–149.[CrossRef][Medline] [Order article via Infotrieve]
22. Nilius B, Prenen J, Kamouchi M, Viana F, Voets T, Droogmans G. Inhibition by mibefradil, a novel calcium channel antagonist, of Ca2+- and volume-activated Cl- channels in macrovascular endothelial cells. Br J Pharmacol. 1997; 121: 547–555.[CrossRef][Medline] [Order article via Infotrieve]
23. Lamb FS, Clayton GH, Liu BX, Smith RL, Barna TJ, Schutte BC. Expression of CLCN voltage-gated chloride channel genes in human blood vessels. J Mol Cell Cardiol. 1999; 31: 657–666.[CrossRef][Medline] [Order article via Infotrieve]
24. Yamazaki J, Duan D, Janiak R, Kuenzli K, Horowitz B, Hume JR. Functional and molecular expression of volume-regulated chloride channels in canine vascular smooth muscle cells. J Physiol. 1998; 507: 729–736.
25. Wang L, Chen L, Jacob TJ. The role of ClC-3 in volume-activated chloride currents and volume regulation in bovine epithelial cells demonstrated by antisense inhibition. J Physiol. 2000; 524: 63–75.
26. Duan D, Zhong J, Hermoso M, Satterwhite CM, Rossow CF, Hatton WJ, Yamboliev I, Horowitz B, Hume JR. Functional inhibition of native volume-sensitive outwardly rectifying anion channels in muscle cells and Xenopus oocytes by anti-ClC-3 antibody. J Physiol. 2001; 531: 437–444.
27. Voets T, Szucs G, Droogmans G, Nilius B. Blockers of volume-activated Cl- currents inhibit endothelial cell proliferation. Pflugers Arch. 1995; 431: 132–134.[CrossRef][Medline] [Order article via Infotrieve]
28. Schlichter LC, Sakellaropoulos G, Ballyk B, Pennefather PS, Phipps DJ. Properties of K+ and Cl- channels and their involvement in proliferation of rat microglial cells. Glia. 1996; 17: 225–236.[CrossRef][Medline] [Order article via Infotrieve]
29. Dick GM, Kong ID, Sanders KM. Effects of anion channel antagonists in canine colonic myocytes: comparative pharmacology of Cl-, Ca2+ and K+ currents. Br J Pharmacol. 1999; 127: 1819–1831.[CrossRef][Medline] [Order article via Infotrieve]
30. Zygmunt AC, Gibbons WR. Calcium-activated chloride current in rabbit ventricular myocytes. Circ Res. 1991; 68: 424–437.
31. Hermoso M, Satterwhite CM, Andrade Y, Hidalgo J, Wilson SM, Horowitz B, Hume JR. ClC-3 is a fundamental molecular component of volume-sensitive outwardly rectifying Cl- channels and volume regulation in HeLa Cells and Xenopus laevis oocytes. J Biol Chem. 2002; 277: 40066–40074.
32. Britton FC, Hatton WJ, Rossow CF, Duan D, Hume JR, Horowitz B. Molecular distribution of volume-regulated chloride channels (ClC-2 and ClC-3) in cardiac tissues. Am J Physiol Heart Circ Physiol. 2000; 279: H2225–H2233.
33. Dick GM, Bradley KK, Horowitz B, Hume JR, Sanders KM. Functional and molecular identification of a novel chloride conductance in canine colonic smooth muscle. Am J Physiol. 1998; 275: C940–C950.[Medline] [Order article via Infotrieve]
34. Schmid A, Blum R, Krause E. Characterization of cell volume-sensitive chloride currents in freshly prepared and cultured pancreatic acinar cells from early postnatal rats. J Physiol. 1998; 513: 453–465.
35. von Weikersthal SF, Barrand MA, Hladky SB. Functional and molecular characterization of a volume-sensitive chloride current in rat brain endothelial cells. J Physiol. 1999; 516: 75–84.
This article has been cited by other articles:
 |
|
 |
|
  R. Tao, C.-P. Lau, H.-F. Tse, and G.-R. Li Functional ion channels in mouse bone marrow mesenchymal stem cells Am J Physiol Cell Physiol, November 1, 2007; 293(5): C1561 - C1567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-G. Zhou, J.-L. Ren, Q.-y. Qiu, H. He, and Y.-Y. Guan Regulation of Intracellular Cl- Concentration through Volume-regulated ClC-3 Chloride Channels in A10 Vascular Smooth Muscle Cells J. Biol. Chem., February 25, 2005; 280(8): 7301 - 7308. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||